LIXT - Lixte Biotech reports that enrollment has resumed in LB-100 trial in brain tumors

Lixte Biotechnology Holdings (LIXT +0.6%) announces that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, enrollment was suspended in 2020 due to COVID-19 restrictions. Those restrictions have now been lifted and patient recruitment has resumed. Up to 20 patients may be enrolled to obtain 8 evaluable subjects. A two-stage design will be used. Five patients will be initially treated. If at least 1 of 5 demonstrates the presence of LB-100 in tumor tissue, 3 additional subjects will be enrolled. If at least 2 of the 8 patients demonstrate LB-100 in tumor tissue, the study will be considered significant providing further support for studying if the addition of LB-100 to standard treatment regimens for malignant brain

For further details see:

Lixte Biotech reports that enrollment has resumed in LB-100 trial in brain tumors